HUE052510T2 - Módszerek a rák és a nem daganatos állapotok kezelésére - Google Patents
Módszerek a rák és a nem daganatos állapotok kezeléséreInfo
- Publication number
- HUE052510T2 HUE052510T2 HUE10781238A HUE10781238A HUE052510T2 HU E052510 T2 HUE052510 T2 HU E052510T2 HU E10781238 A HUE10781238 A HU E10781238A HU E10781238 A HUE10781238 A HU E10781238A HU E052510 T2 HUE052510 T2 HU E052510T2
- Authority
- HU
- Hungary
- Prior art keywords
- methods
- treating cancer
- neoplastic conditions
- neoplastic
- conditions
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18165309P | 2009-05-27 | 2009-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE052510T2 true HUE052510T2 (hu) | 2021-05-28 |
Family
ID=43223094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10781238A HUE052510T2 (hu) | 2009-05-27 | 2010-05-27 | Módszerek a rák és a nem daganatos állapotok kezelésére |
Country Status (13)
Country | Link |
---|---|
US (5) | US9351964B2 (hu) |
EP (2) | EP2434891B9 (hu) |
JP (2) | JP5898067B2 (hu) |
CN (2) | CN106167488A (hu) |
AU (1) | AU2016208323B2 (hu) |
CA (4) | CA3080983C (hu) |
ES (1) | ES2826950T3 (hu) |
HU (1) | HUE052510T2 (hu) |
MX (2) | MX2020005345A (hu) |
PL (1) | PL2434891T3 (hu) |
PT (1) | PT2434891T (hu) |
TW (2) | TWI574961B (hu) |
WO (1) | WO2010138758A1 (hu) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551463B2 (en) | 2007-10-22 | 2013-10-08 | Living Proof, Inc. | Hair care compositions and methods of treating hair |
EP2435437A4 (en) | 2009-05-27 | 2012-10-31 | Ptc Therapeutics Inc | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES |
WO2010138652A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating kaposi sarcoma |
MX2020005345A (es) | 2009-05-27 | 2022-07-18 | Ptc Therapeutics Inc | Un método para inhibir o reducir una infección viral por coronavirus. |
WO2010138685A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
FR2975600B1 (fr) * | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
CN103450196B (zh) * | 2012-05-29 | 2015-07-08 | 首都医科大学 | Agdv肽修饰的咔啉并六氢吡嗪-1,4-二酮、其制备方法、抗血栓作用和应用 |
KR102122244B1 (ko) | 2012-08-28 | 2020-06-15 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
GB201303184D0 (en) * | 2013-02-22 | 2013-04-10 | Virttu Biolog Ltd | Treatment of cancer |
CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
WO2014145751A2 (en) * | 2013-03-15 | 2014-09-18 | The Translational Genomics Research Institute | Targeted therapies for cancer |
CA2922302C (en) | 2013-04-03 | 2021-08-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
SI3004090T1 (en) * | 2013-05-28 | 2018-01-31 | Astrazeneca Ab | Chemical compounds |
LT3024819T (lt) | 2013-07-25 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui |
TWI489307B (zh) * | 2013-09-06 | 2015-06-21 | Univ Nat Yang Ming | Evaluation method and system of blood brain barrier recovery curve |
AP2016009122A0 (en) * | 2013-10-23 | 2016-03-31 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
SG11201606370YA (en) | 2014-02-06 | 2016-09-29 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
KR102505901B1 (ko) * | 2014-06-27 | 2023-03-08 | 노그라 파마 리미티드 | 아릴 수용체 조정제, 및 그의 제조 및 사용 방법 |
EA032311B1 (ru) * | 2014-12-18 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение |
MA41614A (fr) * | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
EA202192092A3 (ru) * | 2015-04-02 | 2022-03-31 | Ф. Хоффманн-Ля Рош Аг | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение |
JP6771023B2 (ja) | 2015-05-06 | 2020-10-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | K−ras調節物質 |
KR20180026459A (ko) | 2015-06-18 | 2018-03-12 | 세파론, 인코포레이티드 | 1,4-치환된 피페리딘 유도체 |
CA3014432C (en) | 2015-06-18 | 2024-05-07 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
CA3178499A1 (en) * | 2015-06-30 | 2017-01-05 | Eiger Group International, Inc. | Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JP6776348B2 (ja) | 2015-10-01 | 2020-10-28 | オレマ ファーマシューティカルズ インク. | テトラヒドロ−1H−ピリド[3,4−b]インドール抗エストロゲン薬物 |
JP2019001715A (ja) * | 2015-10-30 | 2019-01-10 | 協和発酵キリン株式会社 | 三環性化合物 |
WO2017172957A1 (en) * | 2016-04-01 | 2017-10-05 | Kalyra Pharmaceuticals, Inc. | Estrogen receptor modulators |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
WO2017210489A1 (en) | 2016-06-01 | 2017-12-07 | M3 Biotechnology, Inc. | Compounds |
JP7018026B2 (ja) * | 2016-06-16 | 2022-02-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
US20180002344A1 (en) * | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
KR102623130B1 (ko) | 2016-10-11 | 2024-01-10 | 듀크 유니버시티 | Er+ 유방암의 라소폭시펜 치료 |
DK3433256T3 (da) | 2016-10-24 | 2019-10-28 | Astrazeneca | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinolinderivat, der er anvendeligt til behandling af cancer |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
WO2018130123A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的五环类化合物及其应用 |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
MY196317A (en) * | 2017-01-30 | 2023-03-24 | Astrazeneca Ab | Estrogen Receptor Modulators |
US20170281651A1 (en) | 2017-03-01 | 2017-10-05 | Corcept Therapeutics, Inc. | Concomitant administration of glucocorticoid receptor modulators and cyp3a or steroidogenesis inhibitors |
SG11201909570PA (en) | 2017-04-20 | 2019-11-28 | Univ California | K-ras modulators |
CN108864080B (zh) * | 2017-05-09 | 2021-10-15 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的四环类化合物及其应用 |
EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
JP2019151631A (ja) * | 2018-03-02 | 2019-09-12 | 国立大学法人 岡山大学 | 植物病害防除剤及び植物病害の防除方法 |
WO2019175657A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
MX2020013236A (es) | 2018-06-06 | 2021-02-22 | Massachusetts Inst Technology | Acido ribonucleico (arn) circular para traduccion en celulas eucariotas. |
ES2951829T3 (es) | 2018-06-21 | 2023-10-25 | Hoffmann La Roche | Formas sólidas de la sal de tartrato de 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)acetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, proceso para su preparación y procedimientos de su uso en el tratamiento de cánceres |
KR20210041589A (ko) * | 2018-08-03 | 2021-04-15 | 피티씨 테라퓨틱스, 인크. | 생체이용 가능한 경구 투여형 |
US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
CN109400604B (zh) * | 2018-10-25 | 2021-09-03 | 河北科技大学 | 2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚类化合物及用途 |
EP3911418A1 (en) * | 2019-01-15 | 2021-11-24 | PTC Therapeutics, Inc. | Method for treating an acute myeloid leukemia |
KR20210130753A (ko) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 |
AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
BR112021023411A2 (pt) | 2019-05-22 | 2022-02-01 | Massachusetts Inst Technology | Composições e métodos de rna circular |
MX2022006854A (es) | 2019-12-04 | 2022-11-30 | Orna Therapeutics Inc | Composiciones y metodos de arn circular. |
AU2021281232A1 (en) | 2020-05-27 | 2022-12-15 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
TR202019788A1 (tr) * | 2020-12-05 | 2022-06-21 | Istanbul Medipol Ueniversitesi | SARS-CoV-2 ANA PROTEAZ ENZİMİNİN KATALİTİK AKTİVİTESİNİ İNHİBE EDEBİLEN KÜÇÜK TERAPÖTİK MOLEKÜLLER |
EP4267578A1 (en) | 2020-12-23 | 2023-11-01 | Recurium IP Holdings, LLC | Estrogen receptor modulators |
CN114478525B (zh) * | 2022-03-28 | 2023-05-30 | 山东京博农化科技股份有限公司 | 一种四氢-β-咔啉吡唑酰胺衍生物及其制备方法和应用 |
WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
WO2024076626A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
CN116354959B (zh) * | 2023-03-10 | 2024-04-19 | 石河子大学 | 一种N-N桥连噻唑单元的β-咔啉衍生物及其制备方法、应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1055203A (en) | 1964-09-16 | 1967-01-18 | Ici Ltd | -ß-carboline derivatives, a process for their manufacture, and compositions containing them |
EP0357122A3 (en) | 1988-08-29 | 1991-10-23 | Duphar International Research B.V | Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties |
JPH03287586A (ja) | 1990-04-02 | 1991-12-18 | Taisho Pharmaceut Co Ltd | テトラヒドロ―β―カルボリン誘導体 |
FR2662940B1 (fr) | 1990-06-08 | 1994-10-14 | Roussel Uclaf | Utilisation de derives de la tetrahydro isoquinoleine pour la preparation de medicaments anti-tumoraux, application a titre de medicaments de derives de la tetrahydro isoquinoleine et produits derives de cette structure. |
JPH04275221A (ja) | 1991-03-01 | 1992-09-30 | Taisho Pharmaceut Co Ltd | 制癌効果増強剤 |
US5206377A (en) | 1991-12-05 | 1993-04-27 | Whitby Research, Inc. | Compounds useful as antiproliferative agents |
US5622960A (en) | 1992-04-14 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Topoisomerase II inhibitors and therapeutic uses therefor |
US5500431A (en) | 1993-04-14 | 1996-03-19 | Eli Lilly And Company | Tetrahydro-β-carbolines |
EP0620222A3 (en) | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
US5403851A (en) | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
JP2000508302A (ja) | 1996-04-04 | 2000-07-04 | エフ.ホフマン―ラ ロッシュ エイジー | 抗転移剤としてのテトラヒドロ―β―カルボリン誘導体の使用 |
FR2748026B1 (fr) | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6093723A (en) | 1996-08-09 | 2000-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | 4-substituted beta-carbolines and analogs thereof |
JP4275221B2 (ja) | 1998-07-06 | 2009-06-10 | リンテック株式会社 | 粘接着剤組成物および粘接着シート |
DE19915178A1 (de) | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
ATE298570T1 (de) | 2000-12-08 | 2005-07-15 | Smithkline Beecham Corp | Antibakterielle verbindungen |
WO2002064591A2 (en) | 2001-02-12 | 2002-08-22 | Lilly Icos Llc | Carboline derivatives |
JP4220779B2 (ja) | 2001-02-12 | 2009-02-04 | リリー アイコス リミテッド ライアビリティ カンパニー | 化学化合物 |
WO2002078680A1 (de) | 2001-02-13 | 2002-10-10 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Gaba-rezeptor-modulatoren zur behandlung neurodegenerativer erkrankungen des auges |
US6720331B2 (en) | 2001-04-03 | 2004-04-13 | National Sun Yat-Sen University | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents |
JP2004536579A (ja) * | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 血管内皮増殖因子2 |
DE60236605D1 (de) | 2001-09-05 | 2010-07-15 | Minerva Biotechnologies Corp | Zusammensetzungen und deren verwendung zur behandlung von krebs |
EP1438310B1 (en) | 2001-10-19 | 2006-12-20 | TransTech Pharma Inc. | Beta-carbolin derivatives as ptp-inhibitors |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
CA2407755A1 (en) | 2002-10-11 | 2004-04-11 | The Hospital For Sick Children | Inhibition of vegf secretion |
WO2004113336A1 (en) | 2003-06-16 | 2004-12-29 | Chroma Therapeutics Limited | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
AU2004257149A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
WO2004113300A1 (ja) | 2003-06-23 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | 新規三環性複素環化合物 |
US20050101623A1 (en) | 2003-07-23 | 2005-05-12 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
CA2554150A1 (en) | 2004-01-23 | 2005-08-04 | Chiron Corporation | Tetrahydrocarboline compounds as anticancer agents |
US20080103213A1 (en) | 2004-03-05 | 2008-05-01 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of neurofibromatosis |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
SG184755A1 (en) | 2004-03-15 | 2012-10-30 | Ptc Therapeutics Inc | Carboline derivatives useful in the inhibition of angiogenesis |
WO2005089765A1 (en) | 2004-03-15 | 2005-09-29 | Howard James R | Enzyme cofactor combination for supplementing pyruvate dehydrogenase and alpha ketogluterate dehydrogenase complexes |
FR2869540B1 (fr) | 2004-04-30 | 2008-05-16 | Centre Nat Rech Scient Cnrse | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers |
BRPI0510139A (pt) | 2004-05-19 | 2007-10-02 | Natural Source Internat | combinações de flavopereirina e alstonina no tratamento e prevenção de cáncer de próstata |
JP2008502738A (ja) | 2004-06-10 | 2008-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトの癌を処置するための、vegfインヒビターの使用 |
EP1776105A2 (en) * | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
EP1786425A1 (en) | 2004-08-02 | 2007-05-23 | SmithKline Beecham Corporation | Useful compounds for hpv infection |
US8946444B2 (en) | 2004-11-23 | 2015-02-03 | Ptc Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control |
WO2007002051A1 (en) * | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
AU2008239598A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
WO2008128100A1 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
EP2201972A1 (en) | 2008-12-23 | 2010-06-30 | Sanofi-Aventis Deutschland GmbH | Fixed dose injection device with resettable drive mechanism |
WO2010138685A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
US20120157401A1 (en) | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
WO2010138706A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
MX2020005345A (es) | 2009-05-27 | 2022-07-18 | Ptc Therapeutics Inc | Un método para inhibir o reducir una infección viral por coronavirus. |
WO2010138652A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating kaposi sarcoma |
WO2011150162A1 (en) | 2010-05-27 | 2011-12-01 | Ptc Therapeutics, Inc. | Methods for treating viral conditions |
TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
JP2019001715A (ja) | 2015-10-30 | 2019-01-10 | 協和発酵キリン株式会社 | 三環性化合物 |
WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS |
EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
KR20210041589A (ko) | 2018-08-03 | 2021-04-15 | 피티씨 테라퓨틱스, 인크. | 생체이용 가능한 경구 투여형 |
-
2010
- 2010-05-27 MX MX2020005345A patent/MX2020005345A/es unknown
- 2010-05-27 CA CA3080983A patent/CA3080983C/en active Active
- 2010-05-27 CN CN201610576145.5A patent/CN106167488A/zh active Pending
- 2010-05-27 TW TW099117065A patent/TWI574961B/zh active
- 2010-05-27 PT PT107812380T patent/PT2434891T/pt unknown
- 2010-05-27 CA CA2999345A patent/CA2999345A1/en not_active Abandoned
- 2010-05-27 JP JP2012513266A patent/JP5898067B2/ja active Active
- 2010-05-27 CA CA2763485A patent/CA2763485C/en active Active
- 2010-05-27 TW TW105129635A patent/TWI671297B/zh active
- 2010-05-27 HU HUE10781238A patent/HUE052510T2/hu unknown
- 2010-05-27 EP EP10781238.0A patent/EP2434891B9/en active Active
- 2010-05-27 MX MX2011012513A patent/MX348817B/es active IP Right Grant
- 2010-05-27 ES ES10781238T patent/ES2826950T3/es active Active
- 2010-05-27 CN CN2010800333584A patent/CN102480957A/zh active Pending
- 2010-05-27 EP EP20176586.4A patent/EP3718405A1/en active Pending
- 2010-05-27 PL PL10781238T patent/PL2434891T3/pl unknown
- 2010-05-27 CA CA3184380A patent/CA3184380A1/en active Pending
- 2010-05-27 WO PCT/US2010/036467 patent/WO2010138758A1/en active Application Filing
- 2010-05-27 US US13/321,257 patent/US9351964B2/en active Active
-
2015
- 2015-11-20 JP JP2015227314A patent/JP2016053078A/ja not_active Withdrawn
-
2016
- 2016-04-20 US US15/133,359 patent/US20160340354A1/en not_active Abandoned
- 2016-07-27 AU AU2016208323A patent/AU2016208323B2/en active Active
-
2018
- 2018-09-05 US US16/121,956 patent/US20190194188A1/en not_active Abandoned
-
2020
- 2020-06-23 US US16/909,394 patent/US11613538B2/en active Active
-
2023
- 2023-03-24 US US18/126,198 patent/US20240043422A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2434891T (pt) | Métodos para tratamento de cancro e afeções não neoplásicas | |
IL276362A (en) | Cancer treatment methods | |
IL218987A0 (en) | Methods and compositions for treating cancer | |
IL227429A0 (en) | The components and methods of cancer treatment | |
EP2755482A4 (en) | COMPOSITIONS AND METHODS OF TREATING CANCER | |
EP2419136A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
EP2456520A4 (en) | CANCER TREATMENT SYSTEMS AND METHODS USING CURIETHERAPY | |
ZA201205004B (en) | Methods for treating pancreatic cancer | |
SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
EP2643001A4 (en) | METHOD OF TREATING CANCER | |
EP2635286A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
EP2504428A4 (en) | METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING | |
HK1189272A1 (zh) | 治療癌症的方法 | |
IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
EP2437738A4 (en) | METHOD AND COMPOSITIONS FOR CANCER TREATMENT | |
EP2640390A4 (en) | METHODS OF TREATING CANCER | |
IL229231A0 (en) | Preparations and methods for the treatment of cancer | |
EP2391211A4 (en) | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | |
IL218230A0 (en) | Method of treating cancer | |
HK1188566A1 (zh) | 治療癌症的組合物和方法 | |
EP2533806A4 (en) | METHODS AND MATERIALS FOR TREATING CANCER | |
EP2411031A4 (en) | Methods and compositions for the treatment of cancer | |
EP2582384A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
EP2537031A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |